When Warren Buffett calls out “gambling” in a record-high market and the Shiller CAPE ratio clears 40, it pays to ask which stocks look built for storms rather than sunshine. Chasing the hottest chart can feel exciting, yet protecting capital often matters more than bragging rights. This piece walks through three defensive stocks exposed to the same headlines you are watching, and how that link could either help or hurt your portfolio.
The stocks highlighted below are a sample of what this defensive theme can look like in practice. The full screen surfaced 9 more U.S. large caps with equally compelling, income-focused narratives that are not covered here.
If you want to identify and analyze the broader defensive universe rather than just this shortlist, head straight to the High-Quality, Low-Volatility US Defensive Stocks screener.
Overview: Royalty Pharma acquires biopharmaceutical royalties and funds drug development, giving investors indirect exposure to long dated healthcare cash flows.
Operations: Royalty Pharma generates US$2.6b in revenue from acquiring biopharmaceutical royalties in the United States, reflecting its focused healthcare model.
Market Cap: US$39.8b
Royalty Pharma fits this defensive screen as a healthcare royalty specialist that turns long dated drug payments into steadier cash flow, and the bullish analyst Narrative on Simply Wall St argues that one part of the model could matter even more than investors currently assume.
"Royalty Pharma has built an R&D co-funding franchise with large pharmaceutical companies, including recent US$500m commitments with Teva and Johnson & Johnson that are booked as contra R&D for partners."
What happens if a single unseen pressure changes how far that royalty pipeline can carry future earnings resilience and dividend capacity.
That pressure point is exactly where the full narrative for Royalty Pharma shows how the R&D royalty engine could be quietly decoupling near term noise from long term cash flow capacity.
Overview: Zoetis develops and sells medicines, vaccines, diagnostics and precision health tools that help keep pets and livestock healthy worldwide.
Operations: Zoetis generates US$4.8b in revenue from the United States and US$4.5b from international markets, plus US$108m from contract manufacturing.
Market Cap: US$34.1b
Zoetis fits this high quality, low volatility defensive screen as an animal health specialist. Demand for pet and livestock treatments tends to track everyday care rather than market cycles, and ValueInvestingSubstack, a Simply Wall St Community investor who wrote the Narrative, argues that one key pressure point inside its core pet segment deserves closer attention.
"The main reason for the recent collapse in the share price was because they reported that the US Companion Animal segment saw a 11% YoY decline in segment revenues. The company cites generics as a potential risk in its financial statements."
What happens if a single unseen pressure changes how far that pet focused drug portfolio can support pricing power and earnings resilience?
That pressure could be masking where Zoetis still has real firepower, and the full narrative for Zoetis explains how generics risk, pricing and new products all intersect.
Overview: Johnson & Johnson is a global healthcare group supplying prescription medicines and medical technologies across oncology, immunology, surgery, orthopedics, cardiovascular and vision care.
Operations: Johnson & Johnson generates US$64.3b from Innovative Medicine and US$35.0b from MedTech, with US$57.0b coming from the United States.
Market Cap: US$687.9b
For a defensive screen built around large, steady dividend payers, Johnson & Johnson offers the kind of diversified healthcare engine that many investors look for. The analyst consensus Narrative on Simply Wall St points to one particular engine room that could matter most as tech volatility and stretched valuations unsettle the broader market.
"Johnson & Johnson anticipates accelerated growth in their portfolio and pipeline, particularly in the Innovative Medicine sector, despite the headwind from STELARA's loss of exclusivity."
What happens if a single unresolved pressure inside MedTech execution and deal related dilution changes how durable those defensive margins really feel?
That unresolved pressure is exactly where the full narrative for Johnson & Johnson maps how MedTech execution, dilution and the broader Johnson & Johnson engine could still be quietly accelerating defensive cash flows.
Some of the next breakout stories are still flying under the radar for now. Before the momentum gets fully caught by the crowd, scan fresh ideas and get in early.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com